

# Anesthesia for Spine Fusion – Intraoperative Management

Updated 3/3/08

## General

IV Access: consider two IVs if no CVP

Noninvasive Monitoring:

Urine Output:

>0.5 cc/kg/hr indicates adequate perfusion in patients with normal renal function

<0.5cc/kg/hr indicates inadequate perfusion, not a furosemide deficit, until proven otherwise

Blood Loss:

EBV = 70 cc/kg

EBL of 50% of EBV triggers evaluation for transfusion of RBCs and / or coagulation factors

Invasive Monitoring:

Arterial BP: consider for freq sampling, aggressive BP mgt, or comorbidities

CVP: consider esp. for re-do, cardiac or renal dysfunction, or difficult IV access

Positioning: document regular eye / face checks

## Neurodiagnostic Monitoring

<i>Degree of Interference</i>	<b>Inhaled gases</b>	<b>Muscle relaxants</b>	<b>Propofol, narcotics, benzodiazepines, dexmedetomidine</b>
SSEP	Dose-related	Minor or none	Minor or none
MEP	Dose-related	Complete	Minor or none
EMG	Minor or none	Complete	Minor or none
Pedicle screw EMG	Minor or none	Complete	Minor or none
Vocal cord EMG	Minor or none	Complete	Minor or none

## Types of Monitoring

SSEPs: Stim peripheral n. → dorsal column sensory tract → cortical (EEG) monitoring

Up to 15 min delay from injury to detection

Affected by inhaled anesthetic agents, temp, BP

Nearly all IV anesthetics OK except propofol in very high doses

Unaffected by muscle relaxants

TC-MEPs: Stim motor cortex → motor tracts → record at peripheral nerves or muscles

Instantaneous response to injury

Even more sensitive to GA than SSEP

Blocked by muscle relaxants

Case reports show interference by dexmedetomidine<sup>1</sup>

EMG: Monitors electrical activity in muscles, either ambient or triggered

Unaffected by GA, but blocked by muscle relaxants

Pedicle screw monitoring: Triggered EMG with stim. at pedicle screw

Blocked by muscle relaxants, unaffected by GA

Vocal cord monitoring: Ambient EMG in CN-X distribution

Blocked by muscle relaxants, unaffected by GA

## Conduct of Anesthesia:

If in doubt, check with surgeon to ascertain which monitoring modalities are actually important for a particular case

For pedicle screw monitoring, there is often a lengthy exposure time during which pt. may be allowed to recover from initial muscle relaxants

SSEP and MEP: consider establishing a baseline low level of inhaled agent, supplemented by IV agents

Adjust anesthetic depth using IV infusion agents, esp. propofol

EMG (incl ped screw and vocal cord):

Use short acting relaxants for intubation

For prone cases, consider rocuronium to prevent coughing / extubation during turning

## Transfusion Reduction Strategies

Deliberate Hypotension (MAP 60-70)

Benefit: not well established; most surgical bleeding is venous, not arterial

Safety beyond moderate range: not well established, especially if combined with acute normovolemic hemodilution

Agents:

Nitroglycerine: available as 200 mcg/ml bottle; 10-50 mcg/min; no adjustment for renal insufficiency

Nicardipine: dilute to 0.1 mg/ml; load at 5→10→15 mg/hr until BP target reached, then 3-5 mg/hr; no adjustment for renal insufficiency

Esmolol: dilute to 10 mg/ml; 0.5-1 mg/kg load (optional), then 100-500 mcg/kg/min; no adjustment for renal insufficiency

### Acute Normovolemic Hemodilution

Probably reduces transfusions when hard transfusion triggers are used, but less clear benefit in real life

Similar efficacy to preop autologous transfusion, but much cheaper

Use of large amounts of colloid may compromise coagulation

Temperature Management: Mild hypothermia (< 1°C) increases both blood loss and transfusion requirement (Shown by meta-analysis, not prospective trial)<sup>2</sup>

### Eye Care<sup>3</sup>

Mechanisms:

Ischemic Optic Neuropathy (ION), Central Retinal Artery Occlusion (CRAO)

“At Risk” patients:

↑ in prolonged surgery, substantial blood loss, or both

No known patient characteristics

No established risk thresholds for: Hb, CVP or intravascular volume, BP, or vasoconstrictor use

Positioning:

ION: no known effect

CRAO: avoid direct ocular pressure; position head level with or above heart if possible

### Glucose Management

“Tight” glucose control (150-180 mg/dl): benefits well established for cardiac surgery; less established for noncardiac surgery

“Tighter” control (80-100 mg/dl): risks, incl stroke, may be elevated, at least in cardiac surgery<sup>4</sup>; benefits not established

Monitoring frequency: suggest once / hour during steady state insulin infusion

### Transfusion Thresholds<sup>5</sup>

PRBCs

Rarely needed if Hb > 10 g/dl

Usually needed if Hb < 6 g/dl

Average transfusion volume = 1-2 units PRBCs

Platelets

Consider checking when EBL > ½ EBV

Rarely needed if plt > 100k

Usually needed if plt < 50k

Average transfusion volume = 6 units, or 1 unit / 10 kg

### Anticoagulation Management

Amicar (ε-aminocaproic acid):

5gm load over 30-60 min.; 1 gm/hr for remainder of case;

Inhibits fibrinolysis;  
Reduce dose in renal insufficiency; no quantitative info available  
Questionable value in spine surgery<sup>6</sup>

#### FFP

Consider checking PT, PTT, fibrinogen when EBL > ½ EBV  
Indicated for correction of excessive bleeding AND:  
INR 2.0, or PTT 2X normal, or s/p transfusion > 70 ml/kg  
Average transfusion volume = 2 units, or 10-15 ml / kg

#### Cryoprecipitate

Rarely needed if fibrinogen > 150 mg/dl  
Usually needed if fibrinogen < 100 mg/dl, or s/p massive transfusion  
Average transfusion volume = 8-10 units, or 1 unit / 10 kg

#### Desmopressin (a.k.a. DDAVP), (not *vasopressin*):

Consider “when excessive bleeding occurs,” or to treat hetastarch-related platelet dysfunction

Dose = 0.3 mcg / kg, diluted, over 15-30 min

#### Recombinant factor VII

Consider when all else fails, and money is no object

Average dose = 100 mcg / kg; may repeat in 30 min

### **Colloid Administration<sup>7</sup> (Hespan)**

Volume expansion must be balanced against effects on coagulation

Negatively affects F-VII, VWF, and platelet function (reduced Gp IIb-IIIa expression), even at recommended doses;

Generally imitates and accelerates dilutional coagulopathy

Prolongs PTT, TEG measures of clot formation and strength

Effects may be offset by desmopressin (0.3 µg/kg), cryoprecipitate, F-VIII concentrate, or platelet transfusion

### **Nonroutine Anesthetic Agents**

Propofol infusion: large bottles available

Dexmedetomidine infusion:

Prepared as 4mcg / ml in NS

0.2 - 0.7 mcg/kg/hr (optional bolus 1 mcg/kg)

Hepatic metabolism

Moderate amnesia, little analgesia

Consider using for tube tolerance during “wake-up vent”

Ketamine

May enhance SSEPs

May reduce narcotic requirement, but also increase PONV

3 mcg/kg/min = low-dose infusion rate

Fentanyl infusion

Infusion rate = 1-4 mcg / kg / hr; varies with concomitant agents

Fentanyl plasma  $t_{1/2}$  greatly prolonged with infusions over 1 hour; little need for end-of-case narcotics

---

<sup>1</sup> Mahmoud, et. al. Loss of Transcranial Electric Motor Evoked Potentials during Pediatric Spine Surgery with Dexmedetomidine. *Anesthesiology* 2007; 106: 393-6.

<sup>2</sup> Rajagopalan, et. al. The Effects of Mild Perioperative Hypothermia on Blood Loss and Transfusion Requirement. *Anesthesiology* 2008; 108:71-7.

<sup>3</sup> ASA Task Force on Perioperative Blindness. *Anesthesiology* 2006; 104: 1319-28.

<sup>4</sup> Gandhl, et. al. Intensive Intraoperative Insulin Therapy versus Conventional Glucose Management during Cardiac Surgery. *Annals of Internal Medicine* 2007; 146: 233-43.

<sup>5</sup> Practice Guidelines for Perioperative Blood Transfusion and Adjuvant Therapies. American Society of Anesthesiologists Task Force on Perioperative Blood Transfusion and Adjuvant Therapies

<sup>6</sup> Zufferey, et. al. Do Antifibrinolytics Reduce Allogeneic Blood Transfusion in Orthopedic Surgery? *Anesthesiology* 2006; 105: 1034-46.

<sup>7</sup> Kozek-Langenecker. Effects of Hydroxyethyl Starch Solutions on Hemostasis. *Anesthesiology* 2005; 103: 654-60.